These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9331004)

  • 21. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function.
    Hoogkamer JF; Kleinbloesem CH; Ouwerkerk M; Högemann A; Nokhodian A; Kirch W; Weidekamm E
    Eur J Clin Pharmacol; 1998 Jun; 54(4):341-5. PubMed ID: 9696961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil.
    Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S29-30. PubMed ID: 9331002
    [No Abstract]   [Full Text] [Related]  

  • 24. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Pietruck F; Kiel G; Birkel M; Stahlheber-Dilg B; Philipp T
    Biopharm Drug Dispos; 2005 May; 26(4):135-41. PubMed ID: 15768377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
    Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers.
    van Lier JJ; van Heiningen PN; Sunzel M
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S27-8. PubMed ID: 9331001
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.
    Meineke I; Feltkamp H; Högemann A; Gundert-Remy U
    Eur J Clin Pharmacol; 1997; 53(3-4):221-8. PubMed ID: 9476035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.
    Schulz EG; Bahri S; Schettler V; Popov AF; Hermann M
    Clin Drug Investig; 2009; 29(11):713-9. PubMed ID: 19813774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
    Stangier J; Su CA; Schöndorfer G; Roth W
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1355-64. PubMed ID: 11185634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
    Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.